Abbotsford, Canada Clinical Trials

A listing of Abbotsford, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming …

hormone therapy
adjuvant chemotherapy
aromatase inhibitor
breast-conserving surgery
core needle biopsy
BCCA-Abbotsford Cancer Centre
 (1.0 away) Contact site
  • 598 views
  • 25 Jul, 2021
  • +318 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.

biliary cancer
lenvatinib
pancreatic cancers
bladder cancer
measurable disease
BC Cancer - Abbotsford ( Site 0200)
 (1.0 away) Contact site
  • 611 views
  • 04 Aug, 2021
  • +90 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is nave to BCG treatment (Cohort B). The primary hypothesis …

Exdeo Clinical Research Inc. ( Site 0165)
 (0.7 away) Contact site
  • 108 views
  • 04 Aug, 2021
  • +138 other locations
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.

invasive bladder cancer
gilbert's syndrome
gemcitabine
neutrophil count
bladder tumor
Exdeo Clinical Research Inc
 (0.9 away) Contact site
  • 1 views
  • 29 Jul, 2021
  • +315 other locations
A Study of Apalutamide in Participants With High-Risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and …

adenocarcinoma
androgens
apalutamide
androgen suppression
metastasis
Exdeo Clinical Research Inc
 (0.9 away) Contact site
  • 291 views
  • 01 Aug, 2021
  • +354 other locations
A Study of TAR-200 in Combination With Cetrelimab TAR-200 Alone or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease.

intravesical bcg
carcinoma in situ
bladder tumor
radical cystectomy
invasive bladder cancer
Exdeo Clinical Research Inc
 (0.9 away) Contact site
  • 0 views
  • 22 Jul, 2021
  • +176 other locations
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

Exdeo Clinical Research Inc.
 (0.7 away) Contact site
  • 0 views
  • 04 Aug, 2021
  • +144 other locations
A Study of Participants With Advanced Prostate Cancer in Canada

The purpose of this study is to document the course of advanced prostate cancer in Canada in terms of disease progression, real-world treatment, and patient management.

adenocarcinoma
androgens
prostate cancer metastatic
ct scan
metastasis
Abbotsford Regional Hospital and Cancer Centre BC Cancer Agency
 (1.0 away) Contact site
  • 207 views
  • 29 Jul, 2021
  • +23 other locations